Fitzsimon_menu

Innovation is happening. Right here.

Fitzsimons Innovation Community is a sprawling campus of leading-edge laboratory workspace where innovative health and life sciences companies of all sizes take their research to the next level to cure diseases, save lives, and improve care.

Smart, inclusive, forward-thinking, and highly educated people lead life sciences innovation in Colorado, the Hub for Health Impact. Together, we welcome life sciences organizations looking to call Colorado home and to collaborate with a robust community already in on the secret: the health and life sciences industry in Colorado is strong and making a global impact on the future of health.

 Move in, and build your vision here—today.

Community

The emphasis is on Community

We called it a community for a reason. From the board of directors to the newest company on campus, everyone at Fitzsimons Innovation Community knows that easy access to collaboration has direct results on success. From idea incubation to final-product manufacturing, your end-to-end innovation can come alive right here on our campus. All that Colorado sunshine is just a bonus.

Community

Cutting-edge discoveries in action

$72M

Capital Raised

Last year, Fitzsimons Innovation Community member companies attracted more than $72M in investments to support R&D, prepare for clinical trials, accelerate commercialization, retain or recruit talent, and expand to new markets.

50%

Companies Fundraising

Fitzsimons Innovation Community member companies are actively involved in fundraising to power their progress.

30%

Companies Launching New Products

Fitzsimons Innovation Community member companies are launching new products and solutions to market.

*Fitzsimons Innovation Community Member Growth Survey responses (January – December 2024)

A heritage of healthcare and innovation

Fitzsimons Innovation Community stands on the grounds that once held the Fitzsimons Army Hospital, where soldiers returning from World War I were treated. The Colorado high altitude has always been a destination for advancements in lung treatment, and 100 years ago, soldiers sought cures for tuberculosis and mustard gas exposure right here.

After the Army decommissioned the hospital in the 1990s, ideas for the current University of Colorado Anschutz Medical Campus and Fitzsimons Innovation Community began to percolate. That rich history of discovery, care, and research continues to inspire our vision a century later.

Our team is on your team

You know best when it comes to your projects, and we know how to keep you up and running with first-class scientific facilities management and community engagement. Our priority is to help you thrive on this campus and we have the proven tools and expertise to make that happen.

Bruce Schmidt

Chief Engineer

Don Larson

Facilities engineer

Juliena Carlson

Property Administrator

Julie Ehler

Controller

Kelly Brough

President & CEO

Kenneth Ho

Chief Operating Officer

Laurie Troge

Chief of Staff

Lyle Artz

Site manager

Sue Niblo

Senior property manager

"It’s amazing to me how many times the conversations between people at Fitzsimons seem to result in great things for the companies here. Startups are getting advice from larger companies about how to properly scale. They’re really helping each other, and it’s exciting to experience."

Robin Shandas

CEO, EnteroTrack

"Fitzsimons Innovation Community is an excellent place to build a life science business at any stage of development."

Roland Marcus

COO, Peak Diagnostic Partners

Community

Fitzsimons Innovation Community News

What Researchers All Know: Location Matters
News | Oct 15, 2025

What Researchers All Know: Location Matters

Colorado Real Estate Journal's latest Health Care and Life Sciences Quarterly features an article from Dr. Terry Fry, Executive Director of the Gates Institute at University of Colorado Anschutz, about how the proximity between academia, biomanufacturing, and industry collaboration at Fitzsimons accelerates the development of life-changing cell and gene therapies.

Verily Launches Landmark Partnership with CU Anschutz and UCHealth
News | Oct 14, 2025

Verily Launches Landmark Partnership with CU Anschutz and UCHealth

Precision health and medicine giant Verily will be partnering with CU Anschutz and UCHealth to create an AI enabled ecosystem entailing research ready biomedical pipelines and datasets. In addition, the partnership is aiming to build curated AI models across a variety of specific therapeutic and drug areas, such as oncology, musculoskeletal and transplant medicine, to name a few. All of this work will be done using CU Anschutz’s vast research datasets via Verily Workbench, one of the company’s flagship products.

RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases
News | Oct 10, 2025

RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases

RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC's BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen's new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.

Medicare Now Reimbursing for EnteroTrack’s Esophageal String Test®, Expanding Access to Patients with Eosinophilic Esophagitis
News | Oct 08, 2025

Medicare Now Reimbursing for EnteroTrack’s Esophageal String Test®, Expanding Access to Patients with Eosinophilic Esophagitis

EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test® (EST), marking a major milestone in access for patients living with eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. The decision means that Medicare beneficiaries can now receive coverage for the EST, which provides a non-endoscopic, minimally invasive method to monitor esophageal inflammation. The test enables clinicians to track disease activity without the need for repeated sedated endoscopies, which are costly, burdensome, and carry procedural risks.

Change Please Named One of Instawork’s Community Partner of the Year Winners
News | Oct 01, 2025

Change Please Named One of Instawork’s Community Partner of the Year Winners

Change Please was named one of Instawork’s Community Partner of the Year winners for 2025. The Community Partner Awards recognized businesses prioritizing hiring from underserved local communities. With a Denver area location at Fitzsimons Innovation Community, the Change Please mission is to tackle homelessness through employment, training, and holistic support is transforming lives.

CU Anschutz Receives $50M Challenge Gift to Transform Mental Health Care
News | Sep 23, 2025

CU Anschutz Receives $50M Challenge Gift to Transform Mental Health Care

The Anschutz Foundation has committed up to $50 million to the University of Colorado Anschutz medical campus to jumpstart a sweeping new initiative in mental health. As a challenge gift, the investment aims to generate $200 million in funding from public and private partners and will create the CU Anschutz Campus Mental Health Collaborative to develop scalable, tech-enabled programs to improve access and interventions for adults and children in need of mental health care.

Aurora Development Permitting System Gets Rave Reviews: Here's Why
News | Sep 22, 2025

Aurora Development Permitting System Gets Rave Reviews: Here's Why

The city of Aurora is growing a reputation for helping developments get off the ground quickly by helping projects make it through the local permitting process without snags.

Onconaut Secures a Fast-Track STTR Grant from NIH/NCI
News | Aug 28, 2025

Onconaut Secures a Fast-Track STTR Grant from NIH/NCI

Onconaut Therapeutics, a privately-held therapeutics company and prior Innosphere client company, has received $2.5M in funding through a Fast-Track Small Business Technology Transfer (STTR) grant from the National Institute of Health, National Cancer Institute (NCI) for Onconaut to develop small molecule drug inhibitor targeting Chromodomain Helicase DNA binding protein (CHD1L), a novel oncogenic target for metastatic colorectal cancer and other cancers. The grant will allow Onconaut to rapidly develop a lead compound suitable for preclinical IND studies as a single agent and in combination with FOLFIRI.

Next Wave of CU Anschutz Marketing Campaign Hits the High Notes
News | Aug 27, 2025

Next Wave of CU Anschutz Marketing Campaign Hits the High Notes

Never Dream Alone, the latest phase of the CU Anschutz advertising campaign, filmed in collaboration with the Colorado Symphony at Boettcher Concert Hall. The music mirrors the process of discovery at CU Anschutz – a lone idea blossoming into new cures and treatments through innovation and collaboration. “This campaign is about our people, their ideas and the power of collaboration,” said Chancellor Don Elliman. “It is by thinking and dreaming big together that we drive advancements in health and medicine. We’re proud to have worked alongside another crown jewel of our state in the Colorado Symphony to create this one-of-a-kind piece.”

NatGeo Spotlights CU Anschutz Research
News | Aug 20, 2025

NatGeo Spotlights CU Anschutz Research

National Geographic spotlighted groundbreaking research led by CU Anschutz experts, uncovering how COVID-19 and the flu may awaken dormant cancer cells. This discovery raises important questions for survivor care and demonstrates how Colorado researchers are advancing knowledge that impacts lives worldwide.

Want to stay on top of what’s happening on campus?

Sign up for regular updates from Fitzsimons Innovation Community.